Q-omics provides the consensus-scored FNBP4 profile across patient tissues and cancer cell-line models. FNBP4 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, FNBP4 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, FNBP4 protein abundance shows 32,021 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UCS, COAD, and LSCC as cancer lineages where FNBP4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FNBP4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FNBP4 survival associations across molecular data types. FNBP4 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FNBP4 RNA expression–survival associations across cancer types. High FNBP4 expression shows unfavorable associations in ACC, KIRC, LIHC and KICH, but favorable associations in UCS and BLCA. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for FNBP4 RNA expression.
This table summarizes FNBP4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 11. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for FNBP4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FNBP4 shows lower tumor expression in KICH and higher tumor expression in COAD, KIRC, LIHC, HNSC and CHOL. The COAD box plot shows higher FNBP4 RNA expression in tumor versus normal tissue (log2 FC = +0.864, t-test p < 0.001).
This table shows molecular features associated with FNBP4 in patient tissues and cancer cell lines. In patient samples, FNBP4 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, FNBP4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Leukemia.
